Comparative Pharmacology
Head-to-head clinical analysis: LORAZ versus OXAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORAZ versus OXAZEPAM.
LORAZ vs OXAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to gamma-aminobutyric acid (GABA) type A receptors at the benzodiazepine binding site, potentiating the effect of GABA, leading to increased chloride ion influx, neuronal hyperpolarization, and inhibition of neurotransmission.
Binds to GABA-A receptor at benzodiazepine binding site, enhancing Cl- ion conductance and increasing inhibitory neurotransmission. Anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects.
2-6 mg orally or intravenously daily in divided doses; usual range 2-10 mg/day
10-30 mg orally 3-4 times daily; maximum 120 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours in healthy adults. Extended in elderly (15–20 hours), hepatic impairment (up to 50 hours), and obesity.
Clinical Note
moderateClorazepic acid + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate."
Clinical Note
moderateOxazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Oxazepam is combined with Fluticasone propionate."
Clinical Note
moderateTerminal elimination half-life is 5-15 hours (mean 8 hours); no active metabolites, thus accumulation is minimal even with repeated dosing.
Renal: ~85% as glucuronide conjugates and ~10% as unchanged drug. Biliary/fecal: ~5%.
Renal (primarily as glucuronide conjugates, with less than 1% unchanged); biliary/fecal excretion is minimal.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
Lorazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol."